Evidence map›Paper›PMID 34770073›Full record

ArticleInternational journal of environmental research and public health2021

Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model.

Jingyuan Yang, Ling Wang, Ziyuan Sun, Fangming Zhu, Yihui Guo, Yan Shen

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Impact of Compensation Gap on Corporate Innovation: Evidence from China's Pharmaceutical Industry.International journal of environmental research and public health · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingyuan YangSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.ORCID 0000-0001-5848-1896
Ling WangSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.
Ziyuan SunSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.
Fangming ZhuSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.
Yihui GuoSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.
Yan ShenSchool of Economics and Management, China University of Mining and Technology, Xuzhou 221116, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

R&D investment is the source of technological innovation of pharmaceutical enterprises, but it will be restricted by the funding level, especially in the context of major public health emergencies occurring more frequently, therefore exploring the impact of monetary policy uncertainty on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises has important theoretical and practical value. Based on the relevant data of Chinese pharmaceutical manufacturing enterprises from 2012 to 2018, this paper studies the impact of monetary policy uncertainty on R&D investment smoothing behavior of pharmaceutical enterprises, and investigates whether there is a threshold effect. First, our results demonstrate that the empirical test results of this article support the hypothesis of R&D investment smoothing behavior of pharmaceutical manufacturing enterprises. Second, there is a negative correlation between monetary policy uncertainty and R&D investment smoothing behavior, and the shorter the period is, the higher the financing constraints of pharmaceutical enterprises are, and the more obvious the negative correlation is. Third, financing constraints have a single threshold effect on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises, with a threshold of -13.7693. Moreover, this conclusion can better promote the virtuous circle of the real economy of financial and pharmaceutical manufacturing enterprises. It is recommended that pharmaceutical manufacturing enterprises establish and improve the enterprise R&D reserve system, reduce the risk of R&D investment, play the role of R&D smoothing, and realize the sustainable development of enterprise R&D.

Indexed as

InvestmentsPharmaceutical PreparationsChinaEmpirical ResearchSustainable DevelopmentUncertaintyPharmaceutical Preparationsfinancing constraintsmonetary policy uncertaintypharmaceutical manufacturing enterprisesR&D investment smoothing behaviorthreshold regression model

Identifiers

PMID34770073
PMCPMC8583370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.